For decades, bone marrow transplants have depended on living donors. The problem is that suitable matches are scarce, leaving thousands of patients waiting each year, and many never receive a transplant.
Kevin Caldwell looked at that and thought: this doesn’t have to be the ceiling.
So he built Ossium Health, a company recovering bone marrow from deceased organ donors. The goal is straightforward, even if the science isn’t: massively expand the supply of life-saving stem cells, and take on an assumption medicine has held onto for generations.
He Bet on Supply Before Anyone Asked for It
Here’s what made Caldwell’s move risky. He put real capital into building a bone marrow bank before there was proven clinical demand for marrow from deceased donors. Nobody was asking for this yet. He built it anyway.
And the technical hurdles were serious. Bone marrow needs tight HLA matching — you can’t just harvest marrow and hand it to whoever’s next in line. Ossium needed enough genetic diversity in its inventory to actually make matches work. It needed specialized processing. Cryopreservation. Real relationships with organ-procurement organizations. All of that, built from scratch, while the existing living-donor system just kept humming along, already established, already trusted.
The market gap was real, too painfully real. Black and African American patients have historically had just a 29 percent chance of finding a fully matched 8/8 donor through the NMDP Registry. White patients? 79 percent. That’s a massive gap. Though it’s worth saying — newer mismatched-donor techniques have closed some of that distance already. So Ossium isn’t just competing against the old system. It’s racing a system that’s actively improving.
Caldwell built anyway.
Investors backed the idea with more than $125 million across three funding rounds. Clinical proof followed: the first successful transplant using banked deceased-donor marrow came in 2024, and by mid-2026, 28 patients worldwide had received the treatment. By June 2026, Riley Children’s Health confirmed that 28 patients worldwide had received transplants using the technology. Including the first successful pediatric case.
That’s real. That’s proof the idea works.
Three Rules From Caldwell’s Approach to Scarcity
Bank the scarce thing before you need it.
When timing and matching create bottlenecks, don’t wait around for demand to show up. Turn unpredictable supply into something searchable, something ready. His words, from the Flux Podcast: “You need a bank of the bone marrow.”
Ossium built its procurement and cryopreservation network first, not in response to individual transplant requests, but ahead of them. By 2020, Caldwell said, the company already had more than 20 recovery partners in place.
Don’t let one scientific outcome carry the whole company.
Build multiple paths around the same core asset. That way, if one clinical program stumbles, or fails outright, the entire platform doesn’t go down with it. His quote: “We’ve rolled all three of those profiles into one.”
Ossium isn’t just a biobank. It’s also a supplier to other cell-therapy developers, and a therapeutics company in its own right. Same donor infrastructure. Three different ways to make it work.
Time is part of the product.
In urgent healthcare situations, just being available can create value, even if the underlying science isn’t some radical breakthrough. His words: “These patients can’t wait for us to complete our clinical study.”
That’s the whole idea behind Ossium’s HOPE program, expanded access to banked marrow for patients who don’t qualify for PRESERVE I. Take the 14-year-old treated at Riley in 2026. Doctors said a living-donor process could’ve taken up to six weeks. Banked marrow let them move immediately instead.
Why Ossium Reset its First Clinical Trial
Here’s the part of Caldwell’s story that doesn’t make the highlight reel: a clinical trial that enrolled zero patients.
Ossium’s original PRESERVE Phase 1 trial was built around mismatched deceased-donor marrow. ClinicalTrials.gov now lists it as withdrawn. Zero enrollment. Reason given: “change in study design.”
What came next, PRESERVE I, is broader. It accepts grafts ranging from partially matched (4/8) to fully matched (8/8), and it runs across multiple transplant centers. Reading between the lines, this looks like a genuine reset. Rather than force a flawed protocol forward, Ossium tore it down and rebuilt how the whole platform gets tested.
The Network Behind the Model
On the funding side: First Round Capital, General Catalyst, Vivo Capital, CPMG, Manta Ray Ventures, Alumni Ventures, and Asahi Kasei are all disclosed backers. BARDA has also partnered with Ossium, specifically on using banked marrow for radiological and nuclear emergency response.
As for protégés, there isn’t one. No public record shows Caldwell running some portfolio of founders he’s mentored or funded.
His real advantage is institutional, not personal. Organ-procurement organizations supply the tissue. Transplant centers generate the clinical evidence. Investors put up capital to build inventory before demand justifies it. Government relationships open doors for non-commercial uses. Ossium says Caldwell has personally led more than 50 business relationships spanning financing, supply, clinical work, and commercial partnerships.
Steal This: Find the Bottleneck Before You Chase the Breakthrough
Take one process in your business. Map it out: request, sourcing, verification, delivery. Then ask yourself one question: which step in that chain only exists because you’re sourcing the asset after demand shows up?
That was Caldwell’s real insight. Medicine didn’t necessarily need a whole new source of stem-cell biology. It needed a new supply architecture, a different way of getting there.
Key Questions About Kevin Caldwell
What is Kevin Caldwell known for?
He’s the CEO and co-founder of Ossium Health, the company banking bone marrow from deceased organ donors to create an on-demand graft source for transplants.
Has deceased-donor bone marrow actually replaced living donors yet?
Not yet. Early transplants and the data so far show it’s feasible; engraftment works. But the numbers are still small, and it’ll take much larger studies before this can be considered a real substitute for existing donor sources.